Deoxyribonucleate sodium with iron complex (Natrii desoxyribonucleas cum Ferro)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antiviral drugs

Immunomodulators

Included in the formulation
  • Ferrovir®
    solution w / m 
    FarmPack, LLC     Russia
    • АТХ:

    J.05.A.X   Other antiviral drugs

    Pharmacodynamics:

    Has immunostimulating and antiviral effect due to sodium deoxyribonucleate. Activates antiviral, antifungal and antimicrobial immunity. Has an antiviral effect in relation to RNA- and DNAcontaining viruses. Iron is a component of hemoglobin, a cofactor of certain enzymes, myoglobin. Iron, entering the body, stimulates erythropoiesis, participates in the transport of oxygen.

    Pharmacokinetics:

    When intramuscular the introduction of the recommended dose of absorption is rapid. TCmax - 0.5 h. The connection with plasma proteins is 90%, the half-life is 36 hours. With repeated administration of the drug every 24 hours for 5 dayThere is a process of its accumulation in the blood and bone marrow. Eliminated by the kidneys by 60% and through the gastrointestinal tract by 30%.

    Indications:

    HIV infection, viral hepatitis C, herpetic infection in HIV-infected patients, tick-borne encephalitis, herpes.

    ICD-10

    I.A50-A64.A60   Anogenital herpetic viral infection [herpes simplex]

    I.A80-A89.A84   Tick-borne viral encephalitis

    I.B00-B09.B00   Infections caused by the herpes simplex virus [herpes simplex]

    I.B00-B09.B02   Shingles [herpes zoster]

    I.B00-B09.B07   Viral Warts

    I.B15-B19.B17.1   Acute hepatitis C

    I.B15-B19.B18.2   Chronic viral hepatitis C

    I.B20-B24.B20   Disease caused by the human immunodeficiency virus [HIV], manifested as infectious and parasitic diseases

    I.B20-B24.B20.3   The disease caused by HIV, with manifestations of other viral infections

    I.B20-B24   Disease caused by the human immunodeficiency virus [HIV]

    I.B25-B34.B25   Cytomegalovirus

    I.B95-B97.B97.7   Papillomaviruses as a cause of diseases classified elsewhere

    Contraindications:

    Pregnancy, breastfeeding, hypersensitivity, children's age.

    Carefully:

    There is no information on the effect of the drug on driving or other mechanisms.

    Pregnancy and lactation:

    Category FDA not determined. Adequate and well-controlled studies on humans and animals have not been conducted. There is no information on the penetration into breast milk.

    Dosing and Administration:

    With HIV: intramuscularly (slowly, for 1-2 minutes) 5 ml of a 1.5% solution 2 times a day for two weeks, a second course in a month and a half. With herpetic infection intramuscularly 5 ml 1.5% solution (75 mg) twice a day, the course is 10 days.

    Side effects:

    Hyperemia, fever, pain at the injection site.

    Overdose:

    There is no information about an overdose of the drug.

    Interaction:

    At simultaneous reception with anticoagulants, hepatoprotectors their action is amplified.

    When used in complex therapy reduces the toxicity and negative impact of concomitant medications (headache, nausea).

    Special instructions:

    To reduce the pain of the drug, with intramuscular injection, the needle is injected deeply, the drug is injected slowly - 1.5-2 minutes, the solution is brought to room temperature. Intravenous administration is not permissible.

    Instructions
    Up